Literature DB >> 26921823

Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys.

Hiroyuki Yamada1, Yasuo Ochi2, Hiroshi Mori2, Satoshi Nishikawa2, Yasuaki Hashimoto2, Yasutomo Nakanishi2, Makoto Tanaka2, Mark Bruce3, Steve Deacon3, Kazuhito Kawabata2.   

Abstract

We examined the effects of ONO-5334, a cathepsin K inhibitor, on bone markers, BMD, strength and histomorphometry in ovariectomized (OVX) cynomolgus monkeys. ONO-5334 (1.2, 6 and 30mg/kg/day, p.o.), alendronate (0.05mg/kg/2weeks, i.v.), or vehicle was administered to OVX monkeys (all groups N=20) for 16months. A concurrent Sham group (N=20) was also treated with vehicle for 16months. OVX significantly increased bone resorption and formation markers and decreased BMD in lumbar vertebra, femoral neck, proximal tibia and distal radius. Alendronate suppressed these parameters to a level similar to that in the Sham-operated monkeys. ONO-5334 at doses 6 and 30mg/kg decreased bone resorption markers to a level roughly half of that in the Sham group, while keeping bone formation markers level above that in the Sham monkeys. Changes in DXA BMD confirmed that ONO-5334 at doses 6 and 30mg/kg increased BMD to a level greater than that in the Sham group in all examined sites. In the proximal tibia, in vivo pQCT analysis showed that ONO-5334 at doses 6 and 30mg/kg suppressed trabecular BMD loss to the sham level. However, ONO-5334 increased cortical BMD, cortical area and cortical thickness to a level greater than that in the Sham group, suggesting that ONO-5334 improves both cortical BMD and cortical geometry. Histomorphometric analysis revealed that ONO-5334 suppressed bone formation rate (BFR) at osteonal site in the midshaft femur but did not influence OVX-induced increase in BFR at either the periosteal or endocortical surfaces. Unlike alendronate, ONO-5334 increased osteoclasts surface (Oc.S/BS) and serum tartrate-resistant acid phosphatise 5b (TRAP5b) activity, highlighting the difference in the mode of action between these two drugs. Our results suggest that ONO-5334 has therapeutic potential not only in vertebral bones, but also in non-vertebral bones.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cathepsin K inhibitor; ONO-5334; Osteoporosis; Ovariectomized cynomolgus monkeys

Mesh:

Substances:

Year:  2016        PMID: 26921823     DOI: 10.1016/j.bone.2016.02.014

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  The precision study of dual energy X-ray absorptiometry for bone mineral density and body composition measurements in female cynomolgus monkeys.

Authors:  Bin Guo; Qijun Cai; Jinci Mai; Lu Hou; Chunyuan Zeng; Jiefeng Gan; Zhiqiang Tan; Yuefeng Li; Yong Cheng; Jingjie Shang; Yongjin Tang; Xueying Ling; Jian Gong; Lu Wang; Hao Xu
Journal:  Quant Imaging Med Surg       Date:  2022-03

2.  Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.

Authors:  Makoto Tanaka; Yoshitaka Hashimoto; Chihiro Hasegawa; Steve Deacon; Richard Eastell
Journal:  BMC Musculoskelet Disord       Date:  2017-06-19       Impact factor: 2.362

3.  Beneficial Effects and Toxicity Studies of Xian-ling-gu-bao on Bone Metabolism in Ovariectomized Rats.

Authors:  Hao Wu; Qingxiang Zhong; Jing Wang; Man Wang; Fang Fang; Zhi Xia; Rongling Zhong; Houcai Huang; Zhongcheng Ke; Yingjie Wei; Liang Feng; Ziqi Shi; E Sun; Jie Song; Xiaobin Jia
Journal:  Front Pharmacol       Date:  2017-05-22       Impact factor: 5.810

4.  Effect of a cathepsin K inhibitor on arthritis and bone mineral density in ovariectomized rats with collagen-induced arthritis.

Authors:  Takahiro Yamashita; Hiroshi Hagino; Ikuta Hayashi; Masako Hayashibara; Atsushi Tanida; Keita Nagira; Ryohei Fukui; Hideki Nagashima
Journal:  Bone Rep       Date:  2018-05-30

5.  Cortical bone mineral density is increased by the cathepsin K inhibitor ONO-5334, which leads to a robust increase in bone strength: results from a 16-month study in ovariectomised cynomolgus monkeys.

Authors:  Hiroyuki Yamada; Yasuo Ochi; Hiroshi Mori; Satoshi Nishikawa; Yasuaki Hashimoto; Makoto Tanaka; Steve Deacon; Kazuhito Kawabata
Journal:  J Bone Miner Metab       Date:  2018-10-24       Impact factor: 2.626

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.